Table 1.

Baseline characteristics of type 2 diabetes patients who received newly prescribed dapagliflozin in primary care practices in Germany (Disease Analyzer)

Variables
N	1,169
Age (years)	62.5 (11.2)
Male (%)	59.3
Private health insurance coverage (%)	12.9
Diabetologist care (%)	22.7
Dapagliflozin therapy (%)
Monotherapy	10.9
Dapagliflozin + metformin	37.1
Dapagliflozin + insulin (±metformin)	33.5
Dapagliflozin + DPP-4i (±metformin)	9.7
Other combinations	8.9
Comorbidity (%)
Macrovascular complications	47.1
Microvascular complications	22.8
Hypertension	78.8
Hyperlipidemia	62.0

Notes: Data are mean (SD) or proportions (%) DPP-4i. Macrovascular complications include coronary heart disease, myocardial infarction, peripheral vascular disease, and stroke. Microvascular complications include retinopathy, nephropathy, and neuropathy.

Abbreviations: DPP-4i, dipeptidyl peptidase-4 inhibitor; SD, standard deviation.